Comparative Efficacy and the Muscarinic Breakthrough: A Comprehensive Network Meta-Analysis of Antipsychotic Interventions for Acute Schizophrenia

Highlights

The following key findings emerge from this comprehensive network meta-analysis (NMA) of pharmacological interventions for acute schizophrenia:

• Clozapine remains the most efficacious antipsychotic for symptom reduction, followed by amisulpride, olanzapine, and risperidone, though confidence in these estimates ranges from low to moderate.
• All 24 studied antipsychotics demonstrated superior efficacy compared to placebo, with standardized mean differences (SMD) ranging from -0.90 to -0.23.
• The 2024-licensed muscarinic receptor agonist, xanomeline-trospium, provides a novel therapeutic pathway that avoids traditional dopamine-related adverse effects but introduces unique cholinergic and anticholinergic profiles.
• Partial dopamine agonists generally exhibited the most favorable overall tolerability profiles among the antidopaminergic class.
• The study highlights the necessity of updating clinical guidelines to reflect small-to-medium clinically relevant differences in efficacy between specific antipsychotic agents.

Background: The Evolution of Schizophrenia Pharmacotherapy

For decades, the pharmacological management of schizophrenia has been dominated by the dopamine hypothesis, leading to the development of first- and second-generation antipsychotics that primarily function through dopamine D2 receptor antagonism or partial agonism. While effective for positive symptoms, these agents often carry a significant burden of adverse effects, including extrapyramidal symptoms (EPS), metabolic syndrome, and hyperprolactinemia, which frequently impede long-term adherence and functional recovery.

The clinical landscape underwent a paradigm shift in 2024 with the licensure of xanomeline-trospium, a first-in-class muscarinic receptor agonist. By targeting M1 and M4 receptors, this agent modulates dopaminergic neurotransmission indirectly (upstream), offering the potential for antipsychotic efficacy without the direct blockade of striatal dopamine receptors. This systematic review and network meta-analysis aimed to provide a rigorous, evidence-based comparison of this new class against traditional antidopaminergic agents, integrating data from both international English and Chinese databases to ensure a global perspective on treatment efficacy and tolerability.

Study Design and Methodology

This study (PROSPERO, CRD42022380708) represents one of the most extensive NMAs in the field of psychiatry. The researchers included blinded and open randomized controlled trials (RCTs) investigating 23 primarily dopamine-receptor blocking medications and the muscarinic receptor agonist xanomeline-trospium. The study population included participants of any age experiencing acute psychotic symptoms of schizophrenia, with trial durations ranging from 3 weeks to 3 months.

A rigorous search strategy was employed, spanning the Cochrane Schizophrenia group’s register, major international databases, and five specific Chinese databases from their inception until July 26, 2024. A notable methodological strength was the direct contact with authors to verify randomization procedures. Of the 5,117 Chinese trials identified, a significant majority were excluded due to lack of author response or identified methodological concerns, ensuring that only high-quality data informed the final analysis.

The primary outcome was the change in overall symptoms of schizophrenia, measured via validated rating scales (e.g., PANSS or BPRS). Secondary outcomes were extensive, covering 32 distinct efficacy and tolerability metrics, including specific symptom clusters (positive, negative, depressive), treatment dropout rates, and a wide array of side effects. Data were synthesized using a random-effects frequentist network meta-analysis, and the quality of evidence was assessed using the Confidence in Network Meta-Analysis (CINeMA) framework.

Key Findings: Efficacy Hierarchies

The analysis included 438 RCTs, with 388 studies comprising 78,193 participants (28,448 women and 49,745 men) providing usable data. For the primary efficacy outcome, 256 double-blind studies involving 58,948 participants were analyzed.

Primary Efficacy Outcomes

Every antipsychotic evaluated was significantly more effective than placebo. The standardized mean differences (SMD) for symptom reduction compared to placebo were as follows:

• Clozapine: -0.90 (95% CI -1.03 to -0.77)
• Amisulpride: -0.71 (95% CI -0.85 to -0.57)
• Olanzapine: -0.63 (95% CI -0.69 to -0.57)
• Risperidone: -0.58 (95% CI -0.64 to -0.53)

At the lower end of the efficacy spectrum, agents such as brexpiprazole (SMD -0.26) and cariprazine (SMD -0.23) showed smaller, though still statistically significant, effects compared to placebo. Clozapine, amisulpride, olanzapine, and risperidone were consistently more efficacious than at least three other antipsychotic medications, establishing a clear upper tier of efficacy for acute symptom management.

The Role of Xanomeline-Trospium

The muscarinic agonist xanomeline-trospium demonstrated moderate efficacy, performing similarly to several established second-generation antipsychotics. While it did not reach the efficacy heights of clozapine or amisulpride in this NMA, its performance confirms that non-dopaminergic pathways are viable and effective targets for treating acute psychosis.

Tolerability and Safety Profiles

The differentiation between agents was most pronounced in the secondary outcomes related to tolerability. The NMA revealed a diverse landscape of side effects that necessitates individualized drug selection.

Dopaminergic Adverse Effects

Traditional antidopaminergic agents showed varying degrees of weight gain, extrapyramidal symptoms, and prolactin elevation. Olanzapine and clozapine were associated with the highest levels of weight gain and metabolic disruption. In contrast, partial dopamine agonists (e.g., aripiprazole, brexpiprazole, and cariprazine) generally exhibited superior tolerability in these domains, with lower risks of motor side effects and hyperprolactinemia.

Muscarinic-Specific Adverse Effects

Xanomeline-trospium presented a unique safety profile. Because it does not block dopamine receptors, it was not associated with EPS or significant weight gain. However, its muscarinic agonism led to a higher incidence of cholinergic adverse events, such as nausea, vomiting, and dyspepsia. The inclusion of trospium (a peripheral muscarinic antagonist) helps mitigate some peripheral cholinergic effects, but gastrointestinal issues remained a notable factor in trial data.

Expert Commentary: Clinical Implications and Future Directions

The findings of this NMA have significant implications for clinical practice and guideline development. For too long, clinical guidelines have often treated second-generation antipsychotics as a largely homogeneous group in terms of efficacy. This study provides robust evidence that small-to-medium differences in efficacy do exist and are clinically relevant. Clinicians should feel empowered to prioritize more efficacious agents like amisulpride or olanzapine when rapid symptom stabilization is the primary goal, while balancing this against the patient’s metabolic risk profile.

A critical discussion point remains the use of clozapine. Despite its superior efficacy, it is often reserved as a third-line treatment due to its risk of agranulocytosis and other severe side effects. However, the researchers suggest that future trials should investigate the earlier use of clozapine in the course of schizophrenia to determine if it can prevent chronification and improve long-term functional outcomes.

Regarding xanomeline-trospium, while the data are promising, the lack of direct head-to-head trials against established antipsychotics is a limitation. Most data for this agent currently come from placebo-controlled trials. Future research must prioritize direct comparisons to determine its exact place in the treatment hierarchy, especially for patients who are sensitive to dopaminergic side effects or those with treatment-resistant symptoms.

Furthermore, the exclusion of a large number of Chinese trials due to methodological uncertainty highlights the ongoing need for global standardization in clinical trial reporting and the importance of data transparency. The inclusion of the verified high-quality Chinese data, however, significantly strengthens the generalizability of these findings across different ethnic and geographic populations.

Conclusion

This network meta-analysis confirms that while all licensed antipsychotics are effective for acute schizophrenia, they are not interchangeable. Clozapine, amisulpride, and olanzapine lead the hierarchy in efficacy, while partial dopamine agonists and the new muscarinic agonist xanomeline-trospium offer distinct advantages in tolerability. The introduction of xanomeline-trospium marks the beginning of a new era in schizophrenia treatment, providing a much-needed alternative for patients who cannot tolerate the adverse effects of dopamine blockade. Clinicians must leverage these data to move toward a model of precision psychiatry, tailoring drug choice to the specific efficacy needs and tolerability concerns of the individual patient.

Funding and Registration

This study was funded by the German Research Foundation, the German Ministry of Research, Technology and Space, and the National Natural Science Foundation of China. It is registered with PROSPERO, number CRD42022380708.

References

1. Schneider-Thoma J, Zhu Y, Qin M, et al. Comparative efficacy and tolerability of antidopaminergic and muscarinic antipsychotics for acute schizophrenia: a network meta-analysis of randomised controlled trials indexed in international English and Chinese databases. Lancet. 2026;407(10531):876-891. doi:10.1016/S0140-6736(25)02365-7.

2. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951-962.

3. Kaul I, Sawchak S, Correll CU, et al. Efficacy and safety of xanomeline and trospium chloride in schizophrenia: a randomized, double-blind, placebo-controlled, phase 3 trial (EMERGENT-2). Lancet. 2024;403(10422):160-170.